Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel-Gemcitabine and Chemoradiotherapy in Stage III NSCLC
NCT00258739Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2001
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoint: Response rate in each arm measured according to RECIST criteria. Started Oct 2001; status: completed.
02
Drugs
docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00258739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00258739.